Vasoprotective VEGF as a candidate for prevention of recurrence of fibrotic diseases such as Dupuytren's contracture.
Dupuytren's contracture is a disease caused by the proliferation of contractile, fibroblastic cells adjacent to the palmar fascia of the hand. Cellular proliferation is apparently related to similar 'fibroblast' proliferation in wound healing, but continues in the absence of wounding. I propose that this is a similar processes to that which happens in the vascular wall during vascular surgery, that the myofibroblasts are at least partially similar to smooth muscle cells in phenotype, and consequently that treatment with VEGF, either as protein or via gene therapy, which has proven successful in controlling aberrant, wounding-related cell proliferation in arterial grafting, may be valuable in preventing recurrence of Dupuytren's disease after surgery.
Bains
William
W
Delta G Ltd., Melbourn, UK. william@delta-g.com
D004387:Dupuytren Contracture / Q000188:drug therapy* / Q000517:prevention & control*; D005355:Fibrosis / Q000188:drug therapy* / Q000517:prevention & control* / Q000601:surgery / Q000628:therapy; D006801:Humans; D055502:Secondary Prevention; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*
D042461:Vascular Endothelial Growth Factor A